<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="iso-abbrev">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="publisher-id">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="publisher-id">ksp</journal-id><journal-title-group><journal-title>Biomolecules &amp; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1976-9148</issn><issn pub-type="epub">2005-4483</issn><publisher><publisher-name>The Korean Society of Applied Pharmacology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5012869</article-id><article-id pub-id-type="pmid">27582553</article-id><article-id pub-id-type="doi">10.4062/biomolther.2016.168</article-id><article-id pub-id-type="publisher-id">bt-24-453</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90 </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jun</surname><given-names>Kyu-Yeon</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Youngjoo</given-names></name><xref rid="c1-bt-24-453" ref-type="corresp"><sup>*</sup></xref></contrib><aff id="af1-bt-24-453">College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, 
<country>Republic of Korea</country></aff></contrib-group><author-notes><corresp id="c1-bt-24-453"><label>*</label>Corresponding Author: E-mail: <email>ykwon@ewha.ac.kr</email>, Tel: +82-2-3277-4653, Fax: +82-2-3277-3051</corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2016</year></pub-date><volume>24</volume><issue>5</issue><fpage>453</fpage><lpage>468</lpage><history><date date-type="received"><day>02</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>11</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Copyright ©2016, The Korean Society of Applied Pharmacology</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>There is a conserved ATPase domain in topoisomerase II (topo II) and heat shock protein 90 (Hsp90) which belong to the GHKL (gyrase, Hsp90, histidine kinase, and MutL) family. </plain></SENT>
<SENT sid="2" pm="."><plain>The inhibitors that target each of topo II and Hsp90 are intensively studied as anti-cancer drugs since they play very important roles in cell proliferation and survival. </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore the development of dual targeting anti-cancer drugs for topo II and Hsp90 is suggested to be a promising area. </plain></SENT>
<SENT sid="4" pm="."><plain>The topo II and Hsp90 inhibitors, known to bind to their ATP binding site, were searched. </plain></SENT>
<SENT sid="5" pm="."><plain>All the inhibitors investigated were docked to both topo II and Hsp90. </plain></SENT>
<SENT sid="6" pm="."><plain>Four candidate compounds as possible dual inhibitors were selected by analyzing the molecular docking study. </plain></SENT>
<SENT sid="7" pm="."><plain>The pharmacophore model of dual inhibitors for topo II and Hsp90 were generated and the design of novel dual inhibitor was proposed. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Topoisomerase II</kwd><kwd>Heat shock protein 90</kwd><kwd>Molecular docking study</kwd><kwd>Design of dual inhibitor</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="8" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="9" pm="."><plain>Topoisomerase II (topo II) and heat shock protein 90 (Hsp90) both contain a conserved ATPase domain and belong to the same family, namely, GHKL (gyrase, Hsp90, histidine kinase, and MutL) domain (Dutta and Inouye, 2000; Chene, 2002). </plain></SENT>
<SENT sid="10" pm="."><plain>ATPase domain in both of these proteins requires ATP to exert important cellular functions such as cell cycle progression, proliferation and survival. </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, inhibitors targeting the ATP binding site of these two proteins through binding in an ATP-competitive manner were searched and characterized in this study. </plain></SENT>
<SENT sid="12" pm="."><plain>Another important biological implication in topo II and Hsp90 is that they are both overexpressed in proliferating cancer cells and have been attractive targets for the development of anti-cancer drugs (Neckers, 2002; Nitiss, 2009a). </plain></SENT>
</text></p><p><text><SENT sid="13" pm="."><plain>Topo II is very important in cellular processes such as transcription and replication by introducing transient breaks in DNA double strand (Nitiss, 2009b). </plain></SENT>
<SENT sid="14" pm="."><plain>Topo II requires ATP binding for its conformational change to solve topological problems in DNA. </plain></SENT>
<SENT sid="15" pm="."><plain>Recently, there are much efforts in developing catalytic inhibitors of topo II in order to overcome the side-effects of topo II poisons such as etoposide (Pogorelcnik et al., 2013). </plain></SENT>
<SENT sid="16" pm="."><plain>Hsp90 is a molecular chaperone which has diverse client proteins involved in tumor growth and survival. </plain></SENT>
<SENT sid="17" pm="."><plain>Therefore, Hsp90 also has been an attractive target for chemotherapeutic development and phase II clinical trial was conducted for Hsp90 inhibitor, 17-allyaminogeldanamycin (17-AAG) (Sidera and Patsavoudi, 2014). </plain></SENT>
<SENT sid="18" pm="."><plain>In 2006, Jenkins and coworkers reported that the topo II and Hsp90 form a complex, and co-treatment of 17-AAG showed synergistic efficacy by enhancing the activity of topo II poison (Barker et al., 2006; Yao et al., 2007). </plain></SENT>
<SENT sid="19" pm="."><plain>From these findings, development of inhibitors that target both ATPase domains of topo II and Hsp90 can be a promising research area. </plain></SENT>
<SENT sid="20" pm="."><plain>There are many advantages of multi-target drugs since they can simultaneously inhibit multiple pathways and escape an undesirable drug-drug interaction which may encounter with co-treatment of single-target drugs (Petrelli and Giordano, 2008). </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>In this review, the topo II and Hsp90 inhibitors that bind to the ATPase domain of each of topo II and Hsp90 are analyzed and the possibility of designing dual inhibitor is explored through molecular modelling studies. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="22" pm="."><plain>METHODS </plain></SENT>
</text></title><sec><title><text><SENT sid="23" pm="."><plain>Molecular docking studies </plain></SENT>
</text></title><p><text><SENT sid="24" pm="."><plain>The 3D structures of the inhibitors of topo II and Hsp90 were sketched using Sybyl X-2.1.1 (Certara L.P., St. Louis, MO, USA). </plain></SENT>
<SENT sid="25" pm="."><plain>All the structures were energetically minimized using Tripos force field and Gasteiger-Hückel charges. </plain></SENT>
<SENT sid="26" pm="."><plain>The structures of ATPase domain of topo II and Hsp90 were retrieved from RCSB Protein Data Bank (PDB entry code: 1ZXM and 3EKR) (Wei et al., 2005; Kung et al., 2008). </plain></SENT>
<SENT sid="27" pm="."><plain>The ligands were extracted and water molecules were removed from the initial x-ray crystal structure. </plain></SENT>
<SENT sid="28" pm="."><plain>The docking was carried out for both of the topo II and Hsp90 inhibitors to topo II and Hsp90 using Surflex-Dock (Jain, 2003). </plain></SENT>
<SENT sid="29" pm="."><plain>The protomol was generated using ligand mode, which used the ligand, extracted from the crystal structure occupying the ATP binding site, to ensure that the inhibitor could bind to the ATP binding site. </plain></SENT>
<SENT sid="30" pm="."><plain>Then polar hydrogens were added to the structure. </plain></SENT>
<SENT sid="31" pm="."><plain>After the protomol generation, ligands were docked using Surflex-Dock Geom and GeomX modes using default parameters. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="32" pm="."><plain>Pharmacophore hypothesis generation </plain></SENT>
</text></title><p><text><SENT sid="33" pm="."><plain>Compounds PU3, 3t, AUY922 and comp. </plain></SENT>
<SENT sid="34" pm="."><plain>14 were used as input molecules to generate pharmacophore model using GASP module implemented in Sybyl X-2.1.1. </plain></SENT>
<SENT sid="35" pm="."><plain>Four molecules selected were used as the data set for the pharmacophore model generations. </plain></SENT>
<SENT sid="36" pm="."><plain>All the features on each of the molecules were used and the default GA parameters were used. </plain></SENT>
<SENT sid="37" pm="."><plain>The parameters used for the calculations were as follows; 100 population size, 1.1 selection pressure, 100000 max operations, 6500 operation increment and 0.01 fitness. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results"><title><text><SENT sid="38" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec><title><text><SENT sid="39" pm="."><plain>Comparison of the structural similarities of ATPase domain of topo II and Hsp90 </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>Among structures of ATPase domain of topo II and Hsp90 deposited in Protein Data Bank (PDB), 1ZXM for topo II and 3EKR and 1BYQ for Hsp90 were chosen for structure comparison and docking. </plain></SENT>
<SENT sid="41" pm="."><plain>The length of the two proteins is 376 and 217 amino acid residues for topo II and Hsp90, respectively. </plain></SENT>
<SENT sid="42" pm="."><plain>The similarity of the two proteins were compared by sequence alignment using BioEdit (Fig. 1) (Hall, 1999). </plain></SENT>
<SENT sid="43" pm="."><plain>Although the sequence identity between the two ATPase domains is 15.8 %, which is rather small value, the overall fold has high similarity where they are superimposable (Fig. 2). </plain></SENT>
</text></p><p><text><SENT sid="44" pm="."><plain>The ATP binding sites of the two proteins can be suggested to have similar environment. </plain></SENT>
<SENT sid="45" pm="."><plain>The amino acid residues involved in binding with the ligand adenylyl-imidophosphate (AMPPNP) or ADP for topo II and Hsp90, respectively, do not coincide exactly, however the properties of each amino acids are conserved. </plain></SENT>
<SENT sid="46" pm="."><plain>For example, in topo II, Asn120 forms hydrogen bond with the N6 amino group of adenine ring, whereas in Hsp90, Asp93 is involved in the hydrogen bond interaction. </plain></SENT>
<SENT sid="47" pm="."><plain>The hydrophobic residue Ile125 in topo II corresponds to the residue of Met98 in Hsp90 which is also hydrophobic. </plain></SENT>
<SENT sid="48" pm="."><plain>Additionally, the size of the ATP binding site of each protein was calculated with Computed Atlas of Surface Topography of proteins (CASTp, <ext-link ext-link-type="uri" xlink:href="http://sts.bioe.uic.edu/castp/">http://sts.bioe.uic.edu/castp/</ext-link>) (Liang et al., 1998). </plain></SENT>
<SENT sid="49" pm="."><plain>As listed in Table 1 and shown in Fig. 3, the calculated area and volume of topo II ATP binding site were 792.2 Å2 and 1077.6 Å3, respectively. </plain></SENT>
<SENT sid="50" pm="."><plain>The ATP binding site’s area and volume of Hsp90 were slightly smaller than topo II, 628.9 Å2 and 971.0 Å3, respectively. </plain></SENT>
<SENT sid="51" pm="."><plain>The mouth opening of the binding pocket was also identified and characterized with CASTp. </plain></SENT>
<SENT sid="52" pm="."><plain>Although the overall pocket size was slightly larger for topo II, the area and the circumcircle of the mouth opening of Hsp90 were larger than topo II, with the values of 167.6 Å2, 78.6 Å and 70.9 Å2, 52.6 Å, respectively. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="53" pm="."><plain>Topo II inhibitors that bind to the ATPase domain </plain></SENT>
</text></title><p><text><SENT sid="54" pm="."><plain>The topo II inhibitors that bind to the topo II ATPase domain were searched. </plain></SENT>
<SENT sid="55" pm="."><plain>The inhibitors can be largely divided into two categories, purine analogues and non-purine analogues. Table 2 lists the topo II inhibitors and gives information about their structures and ATPase inhibition activity where applicable. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>Purine analogue inhibitors contain the purine ring and have substitutions on the 2, 6, or 9 positions. </plain></SENT>
<SENT sid="57" pm="."><plain>In order to develop novel topo II catalytic inhibitors, 1,990 compounds from the National Cancer Institute (NCI) diversity set library was screened and S6-substituted thioguanine analog, NSC35866 was identified (Jensen et al., 2005). </plain></SENT>
<SENT sid="58" pm="."><plain>This finding was further expanded to discover more potent ATPase inhibitors by screening 40 substituted purine or purine-like compounds in the NCI database and several compounds including NSC348400 were identified from this screening (Jensen et al., 2006). </plain></SENT>
<SENT sid="59" pm="."><plain>Compounds 1 and 2 were searched from the Novartis compound collection to specifically target the ATP binding site of topo II (Furet et al., 2009). </plain></SENT>
<SENT sid="60" pm="."><plain>The hydrogen bond forming residues of topo II were Asn120 and Asn91 which were identical in three topo II complexes with compounds 1, 2 and AMPPNP, however the purine ring of compounds 1 and 2 adopted different orientation compared to that of ATP. </plain></SENT>
<SENT sid="61" pm="."><plain>Compounds 1 and 2 were further optimized by considering these interactions with the binding site and obtained a purine analogue with substitution of an ethyl group at position C6 and a morpholino-ethoxy group in the quinolone substituted on position N2 (called quinoline amino-purine, QAP1) (Chene et al., 2009). </plain></SENT>
<SENT sid="62" pm="."><plain>QAP1 showed improvement in topo II ATPase inhibitory activity with the half maximal inhibitory concentration (IC50) of 128 ± 21 nM. </plain></SENT>
<SENT sid="63" pm="."><plain>3t has a new scaffold, aloisine moiety, which is similar to purine ring (Li et al., 2016). </plain></SENT>
<SENT sid="64" pm="."><plain>In contrast to compounds 1 and 2, the aloisine ring was aligned with the purine ring of ATP from docking study. </plain></SENT>
<SENT sid="65" pm="."><plain>2c is a organoplatinum(II) complex with an attachment of 2-amino-6-chloropurine (Wang et al., 2010). </plain></SENT>
<SENT sid="66" pm="."><plain>2c inhibited topo II by preventing ATP entering into the ATPase domain. </plain></SENT>
<SENT sid="67" pm="."><plain>Although 2c is a purine analog, its purine moiety did not occupy the ATP purine ring binding site, but the tert-butyl groups of the terpyridine scaffold occupied on it, determined by molecular docking study. </plain></SENT>
<SENT sid="68" pm="."><plain>8-chloro-adenosine (8-Cl-Ado) is an anti-cancer agent currently undergoing phase I/II clinical trial. </plain></SENT>
<SENT sid="69" pm="."><plain>8-Cl-Ado converted into 8-Cl-ATP in cells and it competed with ATP to inhibit topo II (Yang et al., 2009). </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>There are some topo II inhibitors originated from natural products. </plain></SENT>
<SENT sid="71" pm="."><plain>Daurinol is a lignan isolated from Haplophyllum dauricum, whose structure is similar to etoposide (Kang et al., 2014). </plain></SENT>
<SENT sid="72" pm="."><plain>Etoposide is a well-known cytotoxic anti-cancer drug functioning as a topo II poison. </plain></SENT>
<SENT sid="73" pm="."><plain>Daurinol occupied the same binding site with AMPPNP, which was shown by molecular docking study, suggesting it inhibited topo II by targeting the ATPase domain. </plain></SENT>
<SENT sid="74" pm="."><plain>Gambogic acid (GA) is a natural product isolated from Garcinia hanburi tree. </plain></SENT>
<SENT sid="75" pm="."><plain>GA was shown to be a catalytic inhibitor of topo II by binding to the ATPase domain, determined by surface plasmon resonance (SPR) analysis and by molecular docking (Qin et al., 2007). </plain></SENT>
<SENT sid="76" pm="."><plain>Diphyllin was extracted from Justicia procumbens, which showed tumoricidal effects. </plain></SENT>
<SENT sid="77" pm="."><plain>D11 is a novel acetylated D-quinovose diphyllin analogue exhibiting potent topo II inhibitory activity and binding to the ATPase domain (Gui et al., 2011). </plain></SENT>
<SENT sid="78" pm="."><plain>When the compound binds to the ATP binding site it is not always a topo II catalytic inhibitor, as it is the case with salvicine and emodin. </plain></SENT>
<SENT sid="79" pm="."><plain>Salvicine is a derivative of diterpenequinone isolated from Salvia prionitis, which bound to the ATPase domain validated by SPR and molecular docking, and acted as a topo II poison generating double strand breaks (Hu et al., 2006). </plain></SENT>
<SENT sid="80" pm="."><plain>Emodin is an anthraquinone isolated from Rheum emodi and also from molds, lichens and fungi. </plain></SENT>
<SENT sid="81" pm="."><plain>Emodin also generated DNA double strand breaks and stabilized the topo II-DNA cleavage complex (Li et al., 2010). </plain></SENT>
</text></p><p><text><SENT sid="82" pm="."><plain>Last group of topo II inhibitors are synthesized compounds designed from different scaffolds known to be biologically active or potent anti-cancer agents. </plain></SENT>
<SENT sid="83" pm="."><plain>Thiosemicarbazone (TSC) is one of the scaffolds, and their derivatives including TSC24 showed catalytic inhibition of topo II (Huang et al., 2010). </plain></SENT>
<SENT sid="84" pm="."><plain>TSC24 directly bound to the ATPase domain which was confirmed by competitive inhibition assay, SPR and molecular docking studies. </plain></SENT>
<SENT sid="85" pm="."><plain>Baviskar and coworkers designed and synthesized bicyclic N-fused aminoimidazole which had similar structure to reported topo II inhibitors and marketed drugs such as zolpidem and zolimidine (Baviskar et al., 2011). </plain></SENT>
<SENT sid="86" pm="."><plain>From the synthesized compounds, comp. </plain></SENT>
<SENT sid="87" pm="."><plain>5 is a non-intercalating topo II catalytic inhibitor that bound to the ATP binding site. </plain></SENT>
<SENT sid="88" pm="."><plain>Compounds 14 and 14mod are xanthone derivatives that bound to the topo II ATPase domain, which was confirmed by ATPase competitive inhibition assay and molecular docking (Jun et al., 2011; Park et al., 2013). </plain></SENT>
<SENT sid="89" pm="."><plain>There were several topo II catalytic inhibitors containing quinone moiety that bound to the ATP binding site. </plain></SENT>
<SENT sid="90" pm="."><plain>Pyranonaphthoquinone, comp. </plain></SENT>
<SENT sid="91" pm="."><plain>3a, was shown to be a topo II catalytic inhibitor and suggested to bind to the ATPase domain through docking (Jimenez-Alonso et al., 2008). </plain></SENT>
<SENT sid="92" pm="."><plain>Naphthoquinone fused cyclic aminoalkyl-phosphonates and aminoalkyl-phosphonic monoester were synthesized and tested for their topo II activity (Wang et al., 2008). </plain></SENT>
<SENT sid="93" pm="."><plain>Some of them including comp. </plain></SENT>
<SENT sid="94" pm="."><plain>18 were catalytic topo II inhibitors and these compounds were docked into the ATP binding site of topo II (Ma et al., 2011). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="95" pm="."><plain>Hsp90 inhibitors that bind to the N-terminal ATPase domain </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>Geldanamycin (GDA) and radicicol (RDC), antibiotic isolated from natural product (Roe et al., 1999) were the first discovered Hsp90 inhibitors that target the N-terminal ATPase domain. </plain></SENT>
<SENT sid="97" pm="."><plain>Due to poor solubility and hepatotoxicity of GDA and RDC, GDA and RDC derivatives were designed and synthesized to have good physical properties and stability with improved potency. </plain></SENT>
<SENT sid="98" pm="."><plain>17-AAG is a GDA derivative that improved the toxicity and stability of GDA itself (Schulte and Neckers, 1998). </plain></SENT>
<SENT sid="99" pm="."><plain>The co-crystal structure of 17-DMAG and Hsp90 N-terminal ATPase domain was solved (Jez et al., 2003). </plain></SENT>
<SENT sid="100" pm="."><plain>GDA derivatives were also genetically engineered to produce GDA analogs, such as KOSN1559, showing better binding affinity than GDA (Patel et al., 2004). </plain></SENT>
</text></p><p><text><SENT sid="101" pm="."><plain>Another group of Hsp90 inhibitors are RDC analogs. </plain></SENT>
<SENT sid="102" pm="."><plain>KF25706, KF29163 and KF58333 were chemically synthesized and their biological activities were assessed (Soga et al., 1999; Agatsuma et al., 2002). </plain></SENT>
<SENT sid="103" pm="."><plain>Various RDC analogs were further synthesized such as aigialmycin D, c-RDC, pochonin A, pochonin D and O-(piperidinocarbonyl) methyloxime derivative of RDC. </plain></SENT>
</text></p><p><text><SENT sid="104" pm="."><plain>The GDA and RDC analogs are rather big in size and their poor properties in solubility and toxicity led to designing and synthesizing purine analogs for inhibiting Hsp90 by binding to the ATP binding site. </plain></SENT>
<SENT sid="105" pm="."><plain>PU3 is one of them and it competed with GDA for Hsp90 binding and when treated in cancer cells, HER2 level decreased (Chiosis et al., 2001). </plain></SENT>
<SENT sid="106" pm="."><plain>Other small Hsp90 inhibitors include pyrazole analogs such as CCT018159 and G3130. </plain></SENT>
<SENT sid="107" pm="."><plain>CCT018159 was searched from high-throughput screening compound collection of more than 56,000 compounds utilizing the ATPase activity assay (Rowlands et al., 2004). </plain></SENT>
<SENT sid="108" pm="."><plain>The crystal structure of G3130 bound to the N-terminal ATP binding domain of Hsp90 was solved and the value of Kd was 280 nM determined by SPR (Kreusch et al., 2005). </plain></SENT>
<SENT sid="109" pm="."><plain>SNX0723 is one of the synthetic compound having a novel scaffold containing benzamide moiety which was discovered to bind to the ATPase domain of Hsp90 by screening a compound library (Putcha et al., 2010). </plain></SENT>
<SENT sid="110" pm="."><plain>Resorcinol moiety was also identified to be an important scaffold for ATPase binding in Hsp90. </plain></SENT>
<SENT sid="111" pm="."><plain>AUY922, AT-13387 and CPUY201112 are the Hsp90 inhibitors that have resorcinol moiety which plays an important role in hydrogen bonding and hydrophobic interactions with the receptor (Dutta Gupta et al., 2014). </plain></SENT>
<SENT sid="112" pm="."><plain>Hsp90 inhibitors targeting its N-terminal ATP binding site reviewed in the current study are listed in Table 3. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="113" pm="."><plain>Molecular docking studies </plain></SENT>
</text></title><p><text><SENT sid="114" pm="."><plain>The similar molecular environment in the ATP binding sites of topo II and Hsp90 led us to assess whether reported inhibitors targeting either topo II or Hsp90 could function as a dual inhibitor. </plain></SENT>
<SENT sid="115" pm="."><plain>The listed topo II and Hsp90 inhibitors mentioned above were subjected for docking against both topo II and Hsp90. Tables 4 and 5 list the docking results of topo II and Hsp90, respectively. </plain></SENT>
<SENT sid="116" pm="."><plain>Surflex-Dock gives total score, crash and polar values for each of conformers. </plain></SENT>
<SENT sid="117" pm="."><plain>Generally, the inhibitors targeting their own binding partner scored high total score. </plain></SENT>
<SENT sid="118" pm="."><plain>Interestingly, the best scoring inhibitor for topo II was PU3, which was reported as an Hsp90 inhibitor with purine ring. </plain></SENT>
<SENT sid="119" pm="."><plain>The inhibitors showing good docking score for Hsp90 did not perform well with topo II ATP binding site. </plain></SENT>
<SENT sid="120" pm="."><plain>This may be due to smaller mouth opening in ATP binding pocket of topo II than Hsp90 which was calculated from CASTp. </plain></SENT>
<SENT sid="121" pm="."><plain>The typical Hsp90 inhibitors are bulkier compared to topo II inhibitors, therefore it would be difficult for bulky Hsp90 inhibitors to enter into the topo II ATP binding pocket. </plain></SENT>
</text></p><p><text><SENT sid="122" pm="."><plain>PU3, 8-Cl-ATP and compound 3t in the docking of topo II, all showed high docking score which are all purine analogs. </plain></SENT>
<SENT sid="123" pm="."><plain>Fascinatingly, PU3, an Hsp90 inhibitor, scored the highest when docked to topo II. </plain></SENT>
<SENT sid="124" pm="."><plain>PU3 had hydrogen bonding interactions with Asn91, Asn120, Ala167 and Thr215, where they are key residues that formed hydrogen bonds with ATP (Fig. 4A). </plain></SENT>
<SENT sid="125" pm="."><plain>Also, PU3 had hydrophobic interactions with the residues comprising the ATP binding pocket, namely, Asn91, Asp94, Arg98, Asn120, Ile125, Ile141, Phe142, Ser149, Asn150, Thr159, Gly161, Arg162, Gly164, Ala167, Lys168 and Thr215. </plain></SENT>
<SENT sid="126" pm="."><plain>Compound 3t also occupied the ATP binding site and interacted with residues Asn91, Ala92, Asn95, Asn120, Pro126, Ile141, Phe142, Ser149, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215 and Ile217 (Fig. 4B). </plain></SENT>
<SENT sid="127" pm="."><plain>However, 3t had only one hydrogen bond interaction with residue Asn91. </plain></SENT>
<SENT sid="128" pm="."><plain>AUY922 is an Hsp90 inhibitor with isoxazole moiety. </plain></SENT>
<SENT sid="129" pm="."><plain>There are two hydroxyl substituents from the phenyl ring and amide group that can form hydrogen bonds with residues Asn95, Asn120 and Ser149. </plain></SENT>
<SENT sid="130" pm="."><plain>Since AUY922 is rather big molecule compared to PU3, 3t, comp. </plain></SENT>
<SENT sid="131" pm="."><plain>14 and 8-Cl-ATP, larger number of residues are involved in van der Waals interaction, namely, Ile88, Asn91, Ala92, Asn95, Arg98, Ile118, Asn120, Il2125, Pro126, Ile141, Phe142, Ser149, Asn150, Gly161, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215 and Ile217. </plain></SENT>
<SENT sid="132" pm="."><plain>Recently from AstraZeneca, compound with benzisoxazole scaffold, ETX0914, was discovered as a novel DNA gyrase inhibitor undergoing phase II clinical trial for the treatment of uncomplicated gonorrhea (Basarab et al., 2015). </plain></SENT>
<SENT sid="133" pm="."><plain>There is no known topo II inhibitor reported with isoxazole scaffold to the best of our knowledge. </plain></SENT>
<SENT sid="134" pm="."><plain>Therefore our docking results suggest AUY922 may act as a topo II inhibitor with novel scaffold. </plain></SENT>
<SENT sid="135" pm="."><plain>Comp. </plain></SENT>
<SENT sid="136" pm="."><plain>14 is a small compound with xanthone moiety which competed with ATP. </plain></SENT>
<SENT sid="137" pm="."><plain>Comp. </plain></SENT>
<SENT sid="138" pm="."><plain>14 had hydrogen bond interactions with Asp94 and Thr215 and hydrophobic interactions with Asn51, Ser52, Ala55, Asp93, Ile96, Gly97, Met98, Asn106, Phe138, Val150, Thr184 and Val186. </plain></SENT>
</text></p><p><text><SENT sid="139" pm="."><plain>In the case of docking topo II and Hsp90 inhibitors to Hsp90, the bulky Hsp90 inhibitors were high in rank as mentioned above. </plain></SENT>
<SENT sid="140" pm="."><plain>However, AUY922, a rather smaller isoxazole derivative compared to classical Hsp90 inhibitors such as GDM or RDC, scored highest. </plain></SENT>
<SENT sid="141" pm="."><plain>AUY922 also had hydrogen bond interactions with five residues in the ATP binding site of Hsp90, Asn51, Lys58, Asp93, Gly97 and Phe138. </plain></SENT>
<SENT sid="142" pm="."><plain>The residues involved in hydrophobic interactions are Asn51, Ala55, Lys59, Asp93, Ile96, Gly97, Met98, Asp102, Leu107, Gly135, Val136, Gly137, Phe138, Val150, Thr184 and Val186. </plain></SENT>
<SENT sid="143" pm="."><plain>PU3, a purine analog Hsp90 inhibitor showed good result in Hsp90 along with 3t, another purine analog topo II inhibitor. </plain></SENT>
</text></p><p><text><SENT sid="144" pm="."><plain>Two purine derivatives of PU3 and 3t and two non-purine compounds of AUY922 and comp. </plain></SENT>
<SENT sid="145" pm="."><plain>14 were selected for further comparison in depth since they ranked high in docking study of both topo II and Hsp90. </plain></SENT>
<SENT sid="146" pm="."><plain>The binding interactions of topo II and Hsp90 with compounds of PU3, 3t, AUY922 and 14 are shown in Fig. 4, 5. </plain></SENT>
<SENT sid="147" pm="."><plain>The hydrogen bonding residues are labeled and the bonds are displayed as light blue dashed lines. </plain></SENT>
<SENT sid="148" pm="."><plain>The selected common four compounds and high scoring compounds 8-Cl-ATP and KOSN1599 for topo II and Hsp90, respectively, were analyzed in detail. Table 6 summarizes the residues involved in hydrophobic and hydrogen bond interactions. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="149" pm="."><plain>Pharmacophore model analysis </plain></SENT>
</text></title><p><text><SENT sid="150" pm="."><plain>Compounds PU3, 3t, AUY922 and comp. </plain></SENT>
<SENT sid="151" pm="."><plain>14 were further evaluated for their dual targeting features by generating pharmacophore models. </plain></SENT>
<SENT sid="152" pm="."><plain>The pharmacophore model was generated using Genetic Algorithm Similarity Program (GASP) module implemented in Sybyl X-2.1.1. </plain></SENT>
<SENT sid="153" pm="."><plain>From the four compounds, four models were generated by GASP. </plain></SENT>
<SENT sid="154" pm="."><plain>The fitness score for each model ranged from 2589.82 to 2689.23 and model 2 was chosen as the best model (Table 7). </plain></SENT>
<SENT sid="155" pm="."><plain>Model 2 consists of two hydrophobic regions (HY, cyan), one acceptor atom (AA, green) and one donor site (DS, green) as shown in Fig. 6 with PU3 as the template. </plain></SENT>
<SENT sid="156" pm="."><plain>The two hydrophobic regions are about 5 Å apart and the hydrophobic region 1 and the acceptor atom is 2.5 Å apart. </plain></SENT>
<SENT sid="157" pm="."><plain>The pharmacophore model suggested here can be used as a template to further optimize the design of the dual inhibitor of topo II and Hsp90. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions"><title><text><SENT sid="158" pm="."><plain>CONCLUSIONS </plain></SENT>
</text></title><p><text><SENT sid="159" pm="."><plain>In this study, the inhibitors reported to target each ATPase domain of human topo II and Hsp90 were investigated. </plain></SENT>
<SENT sid="160" pm="."><plain>The structures of ATPase domains of topo II and Hsp90 were compared to evaluate how similar the environment of the receptor sites were. </plain></SENT>
<SENT sid="161" pm="."><plain>The topo II and Hsp90 inhibitors known to target the ATP binding site were searched and the possibility to function as a dual inhibitor was investigated in silico. </plain></SENT>
<SENT sid="162" pm="."><plain>All the inhibitors searched were docked to both topo II and Hsp90. </plain></SENT>
<SENT sid="163" pm="."><plain>Through the analysis of docking results, four candidate compounds were selected as possible dual inhibitors. </plain></SENT>
<SENT sid="164" pm="."><plain>These compounds were used as a template to generate pharmacophore model. </plain></SENT>
<SENT sid="165" pm="."><plain>This suggested pharmacophore model will be useful in developing dual inhibitor of topo II and Hsp90 by constructing 3D query for virtual screening using publically available database such as ZINC (<ext-link ext-link-type="uri" xlink:href="http://zinc.docking.org/">http://zinc.docking.org/</ext-link>). </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="166" pm="."><plain>This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2013R1A1A2060408), the Korean Health Technology R&amp;D Project funded by Ministry of Health &amp; Welfare, Republic of Korea (HI14C2469), and by the grant of the Bio &amp; Medical Technology Development Program (NRF-2014M3A9A9073 908) of the National Research Foundation of Korea (NRF), funded by the Korean government (Ministry of Science, ICT &amp; Future Planning). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="b1-bt-24-453"><text><SENT sid="167" pm="."><plain>AgatsumaTOgawaHAkasakaKAsaiAYamashitaYMizukamiTAkinagaSSaitohY2002Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activitiesBioorg Med Chem103445345410.1016/S0968-0896(02)00260-2<?supplied-pmid 12213458?>12213458 </plain></SENT>
</text></ref><ref id="b2-bt-24-453"><text><SENT sid="168" pm="."><plain>BarkerCRHamlettJPenningtonSRBurrowsFLundgrenKLoughRWatsonAJJenkinsJR2006The topoisomerase II-Hsp90 complex: A new chemotherapeutic target?Int. </plain></SENT>
<SENT sid="169" pm="."><plain>J. </plain></SENT>
<SENT sid="170" pm="."><plain>Cancer1182685269310.1002/ijc.2171716385570 </plain></SENT>
</text></ref><ref id="b3-bt-24-453"><text><SENT sid="171" pm="."><plain>BasarabGSKernGHMcNultyJMuellerJPLawrenceKVishwanathanKAlmRABarvianKDoigPGalulloVGardnerHGowravaramMHubandMKimzeyAMorningstarMKutschkeALahiriSDPerrosMSinghRSchuckVJTommasiRWalkupGNewmanJV2015Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesSci Rep51182710.1038/srep11827<?supplied-pmid 26168713?>26168713 </plain></SENT>
</text></ref><ref id="b4-bt-24-453"><text><SENT sid="172" pm="."><plain>BaviskarATMadaanCPreetRMohapatraPJainVAgarwalAGuchhaitSKKunduCNBanerjeeUCBharatamPV2011N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIαand induce apoptosis in G1/S phaseJ Med Chem545013503010.1021/jm200235u<?supplied-pmid 21644529?>21644529 </plain></SENT>
</text></ref><ref id="b5-bt-24-453"><text><SENT sid="173" pm="."><plain>BroughPAAherneWBarrilXBorgognoniJBoxallKCansfieldJECheungKMCollinsIDaviesNGDrysdaleMJDymockBEcclesSAFinchHFinkAHayesAHowesRHubbardREJamesKJordanAMLockieAMartinsVMasseyAMatthewsTPMcDonaldENorthfieldCJPearlLHProdromouCRaySRaynaudFIRoughleySDSharpSYSurgenorAWalmsleyDLWebbPWoodMWorkmanPWrightL20084,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancerJ Med Chem5119621810.1021/jm701018h18020435 </plain></SENT>
</text></ref><ref id="b6-bt-24-453"><text><SENT sid="174" pm="."><plain>CheneP2002ATPases as drug targets: Learning from their structureNat Rev Drug Discov166567310.1038/nrd894<?supplied-pmid 12209147?>12209147 </plain></SENT>
</text></ref><ref id="b7-bt-24-453"><text><SENT sid="175" pm="."><plain>ChenePRudloffJSchoepferJFuretPMeierPQianZSchlaeppiJMSchmitzRRadimerskiT2009Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogueBMC Chem Biol9110.1186/1472-6769-9-1<?supplied-pmid 19128485?>19128485 </plain></SENT>
</text></ref><ref id="b8-bt-24-453"><text><SENT sid="176" pm="."><plain>ChiosisGTimaulMNLucasBMunsterPNZhengFFSepp-LorenzinoLRosenN2001A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cellsChem Biol828929910.1016/S1074-5521(01)00015-1<?supplied-pmid 11306353?>11306353 </plain></SENT>
</text></ref><ref id="b9-bt-24-453"><text><SENT sid="177" pm="."><plain>Dutta GuptaSSnigdhaDMazairaGIGalignianaMDSubrahmanyamCVGowrishankarNLRaghavendraNM2014Molecular docking study, synthesis and biological evaluation of schiff bases as Hsp90 inhibitorsBiomed Pharmacother6836937610.1016/j.biopha.2014.01.003<?supplied-pmid 24486109?>24486109 </plain></SENT>
</text></ref><ref id="b10-bt-24-453"><text><SENT sid="178" pm="."><plain>DuttaRInouyeM2000GHKL, an emergent ATPase/kinase superfamilyTrends Biochem Sci25242810.1016/S0968-0004(99)01503-0<?supplied-pmid 10637609?>10637609 </plain></SENT>
</text></ref><ref id="b11-bt-24-453"><text><SENT sid="179" pm="."><plain>FuretPSchoepferJRadimerskiTChèneP2009Discovery of a new class of catalytic topoisomerase II inhibitors targeting the atp-binding site by structure based design. </plain></SENT>
<SENT sid="180" pm="."><plain>Part IBioorg Med Chem Lett194014401710.1016/j.bmcl.2009.06.034<?supplied-pmid 19560355?>19560355 </plain></SENT>
</text></ref><ref id="b12-bt-24-453"><text><SENT sid="181" pm="."><plain>GuiMShiDKHuangMZhaoYSunQMZhangJChenQFengJMLiuCHLiMLiYXGengMDingJ2011D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIαInvest. </plain></SENT>
<SENT sid="182" pm="."><plain>New Drugs2980081010.1007/s10637-010-9425-320336347 </plain></SENT>
</text></ref><ref id="b13-bt-24-453"><text><SENT sid="183" pm="."><plain>HallTA1999BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/ntNucl Acids Symp Ser419598 </plain></SENT>
</text></ref><ref id="b14-bt-24-453"><text><SENT sid="184" pm="."><plain>HuCXZuoZLXiongBMaJGGengMYLinLPJiangHLDingJ2006Salvicine functions as novel topoisomerase II poison by binding to ATP pocketMol Pharmacol701593160110.1124/mol.106.027714<?supplied-pmid 16914642?>16914642 </plain></SENT>
</text></ref><ref id="b15-bt-24-453"><text><SENT sid="185" pm="."><plain>HuangHChenQKuXMengLLinLWangXZhuCWangYChenZLiMJiangHChenKDingJLiuH2010A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase iialpha catalytic activityJ Med Chem533048306410.1021/jm9014394<?supplied-pmid 20353152?>20353152 </plain></SENT>
</text></ref><ref id="b16-bt-24-453"><text><SENT sid="186" pm="."><plain>IkuinaYAmishiroNMiyataMNarumiHOgawaHAkiyamaTShiotsuYAkinagaSMurakataC2003Synthesis and antitumor activity of novel o-carbamoylmethyloxime derivatives of radicicolJ Med Chem462534254110.1021/jm030110r<?supplied-pmid 12773056?>12773056 </plain></SENT>
</text></ref><ref id="b17-bt-24-453"><text><SENT sid="187" pm="."><plain>JainAN2003Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engineJ Med Chem4649951110.1021/jm020406h<?supplied-pmid 12570372?>12570372 </plain></SENT>
</text></ref><ref id="b18-bt-24-453"><text><SENT sid="188" pm="."><plain>JensenLHLiangHShoemakerRGrauslundMSehestedMHasinoffBB2006A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogsMol Pharmacol701503151310.1124/mol.106.026856<?supplied-pmid 16880287?>16880287 </plain></SENT>
</text></ref><ref id="b19-bt-24-453"><text><SENT sid="189" pm="."><plain>JensenLHThougaardAVGrauslundMSokildeBCarstensenEVDvingeHKScudieroDAJensenPBShoemakerRHSehestedM2005Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitorsCancer Res657470747710.1158/0008-5472.CAN-05-0707<?supplied-pmid 16103101?>16103101 </plain></SENT>
</text></ref><ref id="b20-bt-24-453"><text><SENT sid="190" pm="."><plain>JezJMChenJCRastelliGStroudRMSantiDV2003Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90Chem Biol1036136810.1016/S1074-5521(03)00075-9<?supplied-pmid 12725864?>12725864 </plain></SENT>
</text></ref><ref id="b21-bt-24-453"><text><SENT sid="191" pm="."><plain>Jimenez-AlonsoSOrellanaHCEstevez-BraunARaveloAGPerez-SacauEMachinF2008Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitorsJ Med Chem516761677210.1021/jm800499x<?supplied-pmid 18816045?>18816045 </plain></SENT>
</text></ref><ref id="b22-bt-24-453"><text><SENT sid="192" pm="."><plain>JunKYLeeEYJungMJLeeOHLeeESPark ChooHYNaYKwonY2011Synthesis, biological evaluation, and molecular docking study of 3-(3′-heteroatom substituted-2′-hydroxy-1′-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitorEur J Med Chem461964197110.1016/j.ejmech.2011.01.011<?supplied-pmid 21419530?>21419530 </plain></SENT>
</text></ref><ref id="b23-bt-24-453"><text><SENT sid="193" pm="."><plain>KangKNhoCWKimNDSongDGParkYGKimMPanCHShinDOhSHOhHS2014Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phaseInt J Oncol45558566<?supplied-pmid 24841075?>24841075 </plain></SENT>
</text></ref><ref id="b24-bt-24-453"><text><SENT sid="194" pm="."><plain>KreuschAHanSBrinkerAZhouVChoiHSHeYLesleySACaldwellJGuXJ2005Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazolesBioorg Med Chem Lett151475147810.1016/j.bmcl.2004.12.087<?supplied-pmid 15713410?>15713410 </plain></SENT>
</text></ref><ref id="b25-bt-24-453"><text><SENT sid="195" pm="."><plain>KungPPFunkLMengJCollinsMZhouJZJohnsonMCEkkerAWangJMehtaPYinMJRodgersCDaviesJF2ndBaymanESmealTMaegleyKAGehringMR2008Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperoneBioorg Med Chem Lett186273627810.1016/j.bmcl.2008.09.081<?supplied-pmid 18929486?>18929486 </plain></SENT>
</text></ref><ref id="b26-bt-24-453"><text><SENT sid="196" pm="."><plain>LiPHZengPChenSBYaoPFMaiYWTanJHOuTMHuangSLLiDGuLQHuangZS2016Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3-b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitorsJ Med Chem5923825210.1021/acs.jmedchem.5b0128426649766 </plain></SENT>
</text></ref><ref id="b27-bt-24-453"><text><SENT sid="197" pm="."><plain>LiYLuanYQiXLiMGongLXueXWuXWuYChenMXingGYaoJRenJ2010Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting atp hydrolysis of topoisomerase IIToxicol Sci11843544310.1093/toxsci/kfq282<?supplied-pmid 20855424?>20855424 </plain></SENT>
</text></ref><ref id="b28-bt-24-453"><text><SENT sid="198" pm="."><plain>LiangJEdelsbrunnerHWoodwardC1998Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand designProtein Sci71884189710.1002/pro.5560070905<?supplied-pmid 9761470?>9761470 </plain></SENT>
</text></ref><ref id="b29-bt-24-453"><text><SENT sid="199" pm="."><plain>MaYWangJGWangBLiZM2011Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitorsJ Mol Model171899190910.1007/s00894-010-0898-y21107989 </plain></SENT>
</text></ref><ref id="b30-bt-24-453"><text><SENT sid="200" pm="."><plain>MoulinEBarluengaSWinssingerN2005aConcise synthesis of pochonin A, an HSP90 inhibitorOrg Lett75637563910.1021/ol052263+16321010 </plain></SENT>
</text></ref><ref id="b31-bt-24-453"><text><SENT sid="201" pm="."><plain>MoulinEZoeteVBarluengaSKarplusMWinssingerN2005bDesign, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analoguesJ Am Chem Soc1276999700410.1021/ja043101w15884943 </plain></SENT>
</text></ref><ref id="b32-bt-24-453"><text><SENT sid="202" pm="."><plain>MurrayCWCarrMGCallaghanOChessariGCongreveMCowanSCoyleJEDownhamRFigueroaEFredericksonMGrahamBMcMenaminRO’BrienMAPatelSPhillipsTRWilliamsGWoodheadAJWoolfordAJ2010Fragment-based drug discovery applied to Hsp90. </plain></SENT>
<SENT sid="203" pm="."><plain>Discovery of two lead series with high ligand efficiencyJ Med Chem535942595510.1021/jm100059d<?supplied-pmid 20718493?>20718493 </plain></SENT>
</text></ref><ref id="b33-bt-24-453"><text><SENT sid="204" pm="."><plain>NeckersL2002Hsp90 inhibitors as novel cancer chemotherapeutic agentsTrends Mol Med8S55S6110.1016/S1471-4914(02)02316-X<?supplied-pmid 11927289?>11927289 </plain></SENT>
</text></ref><ref id="b34-bt-24-453"><text><SENT sid="205" pm="."><plain>NitissJL2009aTargeting DNA topoisomerase II in cancer chemotherapyNat. </plain></SENT>
<SENT sid="206" pm="."><plain>Rev. </plain></SENT>
<SENT sid="207" pm="."><plain>Cancer933835010.1038/nrc260719377506 </plain></SENT>
</text></ref><ref id="b35-bt-24-453"><text><SENT sid="208" pm="."><plain>NitissJL2009bDNA topoisomerase II and its growing repertoire of biological functionsNat. </plain></SENT>
<SENT sid="209" pm="."><plain>Rev. </plain></SENT>
<SENT sid="210" pm="."><plain>Cancer932733710.1038/nrc260819377505 </plain></SENT>
</text></ref><ref id="b36-bt-24-453"><text><SENT sid="211" pm="."><plain>ParkSEChangIHJunKYLeeELeeESNaYKwonY20133-(3-butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damageEur J Med Chem6913914510.1016/j.ejmech.2013.07.048<?supplied-pmid 24013413?>24013413 </plain></SENT>
</text></ref><ref id="b37-bt-24-453"><text><SENT sid="212" pm="."><plain>PatelKPiagentiniMRascherATianZQBuchananGORegentinRHuZHutchinsonCRMcDanielR2004Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibitionChem Biol111625163310.1016/j.chembiol.2004.09.012<?supplied-pmid 15610846?>15610846 </plain></SENT>
</text></ref><ref id="b38-bt-24-453"><text><SENT sid="213" pm="."><plain>PetrelliAGiordanoS2008From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantageCurr Med Chem1542243210.2174/092986708783503212<?supplied-pmid 18288997?>18288997 </plain></SENT>
</text></ref><ref id="b39-bt-24-453"><text><SENT sid="214" pm="."><plain>PogorelcnikBPerdihASolmajerT2013Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agentsCurr Med Chem2069470910.2174/09298671380499940223210851 </plain></SENT>
</text></ref><ref id="b40-bt-24-453"><text><SENT sid="215" pm="."><plain>PutchaPDanzerKMKranichLRScottASilinskiMMabbettSHicksCDVealJMSteedPMHymanBTMcLeanPJ2010Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicityJ Pharmacol Exp Ther33284985710.1124/jpet.109.15843619934398 </plain></SENT>
</text></ref><ref id="b41-bt-24-453"><text><SENT sid="216" pm="."><plain>QinYMengLHuCDuanWZuoZLinLZhangXDingJ2007Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domainMol Cancer Ther62429244010.1158/1535-7163.MCT-07-0147<?supplied-pmid 17876042?>17876042 </plain></SENT>
</text></ref><ref id="b42-bt-24-453"><text><SENT sid="217" pm="."><plain>RoeSMProdromouCO’BrienRLadburyJEPiperPWPearlLH1999Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycinJ Med Chem4226026610.1021/jm980403y<?supplied-pmid 9925731?>9925731 </plain></SENT>
</text></ref><ref id="b43-bt-24-453"><text><SENT sid="218" pm="."><plain>RowlandsMGNewbattYMProdromouCPearlLHWorkmanPAherneW2004High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activityAnal Biochem32717618310.1016/j.ab.2003.10.038<?supplied-pmid 15051534?>15051534 </plain></SENT>
</text></ref><ref id="b44-bt-24-453"><text><SENT sid="219" pm="."><plain>SchulteTWNeckersLM1998The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycinCancer Chemother Pharmacol4227327910.1007/s002800050817<?supplied-pmid 9744771?>9744771 </plain></SENT>
</text></ref><ref id="b45-bt-24-453"><text><SENT sid="220" pm="."><plain>SideraKPatsavoudiE2014HSP90 inhibitors: current development and potential in cancer therapyRecent Pat Anticancer Drug Discov912010.2174/1574892811308999003123312026 </plain></SENT>
</text></ref><ref id="b46-bt-24-453"><text><SENT sid="221" pm="."><plain>SogaSNeckersLMSchulteTWShiotsuYAkasakaKNarumiHAgatsumaTIkuinaYMurakataCTamaokiTAkinagaS1999KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling moleculesCancer Res5929312938<?supplied-pmid 10383157?>10383157 </plain></SENT>
</text></ref><ref id="b47-bt-24-453"><text><SENT sid="222" pm="."><plain>SogaSSharmaSVShiotsuYShimizuMTaharaHYamaguchiKIkuinaYMurakataCTamaokiTKurebayashiJSchulteTWNeckersLMAkinagaS2001Stereospecific antitumor activity of radicicol oxime derivativesCancer Chemother Pharmacol4843544510.1007/s00280010037311800023 </plain></SENT>
</text></ref><ref id="b48-bt-24-453"><text><SENT sid="223" pm="."><plain>WangBMiaoZWWangJChenRYZhangXD2008Synthesis and biological evaluation of novel naphthoquinone fused cyclic aminoalkylphosphonates and aminoalkylphosphonic monoesterAmino Acids3546346810.1007/s00726-007-0570-817665273 </plain></SENT>
</text></ref><ref id="b49-bt-24-453"><text><SENT sid="224" pm="."><plain>WangPLeungCHMaDLLuWCheCM2010Organoplatinum(II) complexes with nucleobase motifs as inhibitors of human topoisomerase II catalytic activityChem Asian J52271228010.1002/asia.201000451<?supplied-pmid 20730852?>20730852 </plain></SENT>
</text></ref><ref id="b50-bt-24-453"><text><SENT sid="225" pm="."><plain>WeiHRuthenburgAJBechisSKVerdineGL2005Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomeraseJ Biol Chem280370413704710.1074/jbc.M506520200<?supplied-pmid 16100112?>16100112 </plain></SENT>
</text></ref><ref id="b51-bt-24-453"><text><SENT sid="226" pm="."><plain>XuXLBaoQCJiaJMLiuFGuoXKZhangMYWeiJLLuMCXuLLZhangXJYouQDSunHP2016CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cellsSci Rep61900410.1038/srep19004 </plain></SENT>
</text></ref><ref id="b52-bt-24-453"><text><SENT sid="227" pm="."><plain>YangSYJiaXZFengLYLiSYAnGSNiJHJiaHT2009Inhibition of topoisomerase ii by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cellsBiochem Pharmacol7743344310.1016/j.bcp.2008.10.02219014910 </plain></SENT>
</text></ref><ref id="b53-bt-24-453"><text><SENT sid="228" pm="."><plain>YangZQGengXSolitDPratilasCARosenNDanishefskySJ2004New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the targetJ Am Chem Soc1267881788910.1021/ja0484348<?supplied-pmid 15212536?>15212536 </plain></SENT>
</text></ref><ref id="b54-bt-24-453"><text><SENT sid="229" pm="."><plain>YaoQWeigelBKerseyJ2007Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51Clin Cancer Res131591160010.1158/1078-0432.CCR-06-1750<?supplied-pmid 17332306?>17332306 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="f1-bt-24-453" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p><text><SENT sid="230" pm="."><plain>The sequence alignment of the ATPase domain of topo II (1ZXM) and Hsp90 (3EKR). </plain></SENT>
<SENT sid="231" pm="."><plain>The alignment were generated using BioEdit. </plain></SENT>
</text></p></caption><graphic xlink:href="bt-24-453f1"/></fig></SecTag><SecTag type="FIG"><fig id="f2-bt-24-453" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p><text><SENT sid="232" pm="."><plain>The structure of ATPase domain of (A) topo II and (B) Hsp90. </plain></SENT>
<SENT sid="233" pm="."><plain>AMPPNP and ADP bound to topo II and Hsp90, respectively are represented in space-filling model colored by atom type (gray: carbon; red: oxygen; blue: nitrogen; orange: phosphorus). </plain></SENT>
<SENT sid="234" pm="."><plain>The proteins are represented in ribbon. </plain></SENT>
</text></p></caption><graphic xlink:href="bt-24-453f2"/></fig></SecTag><SecTag type="FIG"><fig id="f3-bt-24-453" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p><text><SENT sid="235" pm="."><plain>The comparison of ATP binding site of (A) topo II and (B) Hsp90. </plain></SENT>
<SENT sid="236" pm="."><plain>The channel was created using MOLCAD implemented in Sybyl, colored by electrostatic potential. </plain></SENT>
<SENT sid="237" pm="."><plain>The color ramp ranges from red (most positive) to purple (most negative). </plain></SENT>
<SENT sid="238" pm="."><plain>AMPPNP and ADP bound to topo II and Hsp90, respectively are represented in sticks colored by atom type (gray: carbon; red: oxygen; blue: nitrogen; orange: phosphorus). </plain></SENT>
<SENT sid="239" pm="."><plain>The proteins are represented in ribbon (blue: β-strand; red: α-helix). </plain></SENT>
</text></p></caption><graphic xlink:href="bt-24-453f3"/></fig></SecTag><SecTag type="FIG"><fig id="f4-bt-24-453" orientation="portrait" position="float"><label>Fig. 4.</label><caption><p><text><SENT sid="240" pm="."><plain>The docking result of the selected inhibitors against topo II. </plain></SENT>
<SENT sid="241" pm="."><plain>The ATP binding site of topo II with inhibitors (A) PU3, (B) 3t, (C) AUY922 and (D) Comp. </plain></SENT>
<SENT sid="242" pm="."><plain>14. </plain></SENT>
<SENT sid="243" pm="."><plain>The ligands are represented in sticks colored by atom type (magenta: carbon; red: oxygen; blue: nitrogen; orange: phosphorus) and the residues involved in hydrogen bonds are shown in dotted line colored in cyan. </plain></SENT>
</text></p></caption><graphic xlink:href="bt-24-453f4"/></fig></SecTag><SecTag type="FIG"><fig id="f5-bt-24-453" orientation="portrait" position="float"><label>Fig. 5.</label><caption><p><text><SENT sid="244" pm="."><plain>The docking result of the selected inhibitors against Hsp90. </plain></SENT>
<SENT sid="245" pm="."><plain>The ATP binding site of topo II with inhibitors (A) PU3, (B) 3t, (C) AUY922, and (D) Comp.14. </plain></SENT>
<SENT sid="246" pm="."><plain>The ligands are represented in sticks colored by atom type (yellow: carbon; red: oxygen; blue: nitrogen; orange: phosphorus) and the residues involved in hydrogen bonds are shown in dotted line colored in cyan. </plain></SENT>
</text></p></caption><graphic xlink:href="bt-24-453f5"/></fig></SecTag><SecTag type="FIG"><fig id="f6-bt-24-453" orientation="portrait" position="float"><label>Fig. 6.</label><caption><p><text><SENT sid="247" pm="."><plain>The pharmacophore model 2 generated from GASP. </plain></SENT>
<SENT sid="248" pm="."><plain>The pharmacophore features are two hydrophobic regions (HY, cyan), one acceptor atom (AA, green) and one donor site (DS, green) with PU3 as the template represented in sticks colored by atom type (gray: carbon; light blue: hydrogen; red: oxygen; blue: nitrogen; orange: phosphorus). </plain></SENT>
</text></p></caption><graphic xlink:href="bt-24-453f6"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="t1-bt-24-453" orientation="portrait" position="float"><label>Table 1.</label><caption><p><text><SENT sid="249" pm="."><plain>The characterization of the active sites of topo II and Hsp90 by CASTp </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" rowspan="3" align="center" colspan="1"><text><SENT sid="250" pm="."><plain>Protein </plain></SENT>
</text></th><th colspan="2" valign="middle" align="center" rowspan="1"><text><SENT sid="251" pm="."><plain>Pocket </plain></SENT>
</text></th><th colspan="3" valign="middle" align="center" rowspan="1"><text><SENT sid="252" pm="."><plain>Mouth </plain></SENT>
</text></th></tr><tr><th colspan="2" valign="middle" align="center" rowspan="1"><text><SENT sid="253" pm="."><plain> </plain></SENT>
</text></th><th colspan="3" valign="middle" align="center" rowspan="1"><text><SENT sid="254" pm="."><plain> </plain></SENT>
</text></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Area (Å2) </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>Volume (Å3) </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>Number* </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Area (Å2) </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>Circumcircle (Å) </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>792.2 </plain></SENT>
</text></td><td valign="middle" align="right" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>1077.6 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>2 </plain></SENT>
</text></td><td valign="middle" align="right" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>70.9 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>52.6 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>628.9 </plain></SENT>
</text></td><td valign="middle" align="right" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>971.0 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>1 </plain></SENT>
</text></td><td valign="middle" align="right" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>167.6 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>78.6 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-bt-24-453"><label>*</label><p>Number of mouth openings for the pocket. Each has to be large enough to allow the solvent probe to pass through.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t2-bt-24-453" orientation="portrait" position="float"><label>Table 2.</label><caption><p><text><SENT sid="272" pm="."><plain>Topo II inhibitors that bind to the ATPase domain </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>Name </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>Structure </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>IC50* </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Type </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>Reference </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>Comp. </plain></SENT>
<SENT sid="279" pm="."><plain>1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>1.7 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>Purine analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>Furet et al., 2009 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>Comp. </plain></SENT>
<SENT sid="285" pm="."><plain>2 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>8.4 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>Purine analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>Furet et al., 2009 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>NSC35866 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>50 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>Purine analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Jensen et al., 2005 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>NCS348400 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>0.39 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>Purine analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>Jensen et al., 2006 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>QAP1 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>128 nM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Purine analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>Chene et al., 2009 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>2c </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>Ki=1.25 µM in ATP competition assay </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>Purine analog with platinum </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>Wang et al., 2010 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>8-Cl-ATP </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>Yang et al., 2009 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>3t </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>1,3-benzoazolyl-substituted pyrrolo[2,3-b]pyrazine derivatives </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>Li et al., 2016 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>Daurinol </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>Natural product </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>Wang et al., 2010 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>TSC24 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>Kd=18.3 µM compared to ATP (615 µM) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>Thiosemicarbazone </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Huang et al., 2010 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>Comp. </plain></SENT>
<SENT sid="327" pm="."><plain>5 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>52.77 µM, Ki=75 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>N-fused imidazole </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>Baviskar et al., 2011 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>Comp. </plain></SENT>
<SENT sid="333" pm="."><plain>14 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>Xanthone </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>Jun et al., 2011 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>Comp. </plain></SENT>
<SENT sid="338" pm="."><plain>14mod </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>Xanthone </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>Park et al., 2013 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>Comp. </plain></SENT>
<SENT sid="343" pm="."><plain>18 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>Naphthoquinone fused cyclic aminoalkyl-phosphonates and aminoalkyl-phosphonic monoester </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>Wang et al., 2008 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>Salvicine </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>Kd=74.3 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Natural product </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>Hu et al., 2006 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>D11 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>Kd=37.7 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>Diphyllin glycoside </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>Gui et al., 2011 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>Gambogic acid </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>Kd=3.32 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>Natural product </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>Qin et al., 2007 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>Emodin </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>Anthraquinone analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>Li et al., 2010 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-bt-24-453"><label>*</label><p>IC<sub>50</sub> values for the compound otherwise noted; inhibition constant (K<sub>i</sub>), dissociation constant (K<sub>d</sub>).</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t3-bt-24-453" orientation="portrait" position="float"><label>Table 3.</label><caption><p><text><SENT sid="366" pm="."><plain>Hsp90 inhibitors that bind to the ATPase domain </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>Name </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>Structure </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>IC50 </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>Type </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>Reference </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>GDA </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>Kd=1.2 µM (determined from isothermal calorimetry (ITC)) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>Roe et al., 1999 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>Radicicol </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>23 nM, Kd=19 nM (ITC) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>Roe et al., 1999 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>17-AAG </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>Geldanamycin derivative </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>Schulte and Neckers, 1998 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>17-DMAG </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>Geldanamycin derivative </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>Jez et al., 2003 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>KOSN1559 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>Kd=16 nM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>Geldanamycin derivative </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>Patel et al., 2004 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>KF25706 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>Soga et al., 1999 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>KF29163 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>Agatsuma et al., 2002 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>c-RDC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>Yang et al., 2004 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>Aigialmycin D </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>Yang et al., 2004 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>Pochonin A </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>90 nM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>Moulin et al., 2005a </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>Pochonin D </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>Moulin et al., 2005b </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>KF58333 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>Soga et al., 2001 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>o-(piperidinocarbonyl) methyloxime derivative of RDC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>RDC analog </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>Ikuina et al., 2003 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>PU3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Kd=15∼20 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>Purine derivative </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>Chiosis et al., 2001 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>PU3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>Kd=15∼20 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>Purine derivative </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>Chiosis et al., 2001 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>CCT018159 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>8.9 µM </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>Pyrazole </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>Rowlands et al., 2004 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>G3130 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>Kd =280 nM (SPR) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Pyrazole </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>Kreusch et al., 2005 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>SNX0723 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>Benzamide </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>Putcha et al., 2010 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>AUY922 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>Resorcinol </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>Brough et al., 2008 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>AT-13387 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>Resorcinol </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>Murray et al., 2010 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>CPUY201112 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain> </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>Resorcinol </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>Xu et al., 2016 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t4-bt-24-453" orientation="portrait" position="float"><label>Table 4.</label><caption><p><text><SENT sid="462" pm="."><plain>Topo II docking results of combined inhibitors </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>Name </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>Target </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>Total Score1 </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>Crash2 </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>Polar3 </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>Similarity4 </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>PU3 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>13.1154 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>−0.9961 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>4.5667 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>0.541 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>8-Cl-ATP </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>11.2764 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>−2.0944 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>11.0551 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>0.527 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>3t </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>10.4766 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>−0.6886 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>1.7276 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>0.397 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>Comp. </plain></SENT>
<SENT sid="488" pm="."><plain>14mod </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>10.2868 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>−2.5358 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>3.0286 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>0.407 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>Comp. </plain></SENT>
<SENT sid="495" pm="."><plain>14 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>9.927 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>−2.1249 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>3.0481 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>0.427 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>AUY922 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>9.8884 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>−3.5617 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>3.1905 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>0.463 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>Salvicine R </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>8.5495 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>−2.5071 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>2.9333 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>0.333 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>CCT018159 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>8.0916 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>−0.9934 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>2.739 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>0.382 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>SNX0723 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>8.034 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>−5.2877 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>2.8872 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>0.443 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>NSC348400 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>7.9712 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>−3.1936 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>5.9702 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>0.568 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>Comp. </plain></SENT>
<SENT sid="532" pm="."><plain>2 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>7.9074 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>−0.4726 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="536" pm="."><plain>2.1046 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="537" pm="."><plain>0.418 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="538" pm="."><plain>Daurinol </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="539" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="540" pm="."><plain>7.564 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="541" pm="."><plain>−1.1849 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>4.962 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>0.459 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="544" pm="."><plain>Comp. </plain></SENT>
<SENT sid="545" pm="."><plain>5 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="546" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain>7.4758 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain>−1.6766 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain>2.5831 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="550" pm="."><plain>0.404 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="551" pm="."><plain>QAP1 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="552" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="553" pm="."><plain>7.3683 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="554" pm="."><plain>−2.2725 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="555" pm="."><plain>2.9142 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="556" pm="."><plain>0.372 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="557" pm="."><plain>G3130 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>7.1866 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain>−0.3941 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>3.5543 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain>0.336 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="563" pm="."><plain>Comp. </plain></SENT>
<SENT sid="564" pm="."><plain>1 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain>7.1634 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain>−1.3298 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>3.7455 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="569" pm="."><plain>0.235 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="570" pm="."><plain>Salvicine S </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="571" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="572" pm="."><plain>7.0436 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="573" pm="."><plain>−2.892 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="574" pm="."><plain>3.1112 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="575" pm="."><plain>0.461 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="576" pm="."><plain>NSC35866 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="577" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="578" pm="."><plain>6.9393 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="579" pm="."><plain>−1.0221 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="580" pm="."><plain>2.0358 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="581" pm="."><plain>0.458 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="582" pm="."><plain>KF58333 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="583" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="584" pm="."><plain>6.7973 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="585" pm="."><plain>−4.5147 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="586" pm="."><plain>2.4482 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="587" pm="."><plain>0.380 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="588" pm="."><plain>CPUY201112 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="589" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="590" pm="."><plain>6.7935 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="591" pm="."><plain>−2.242 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="592" pm="."><plain>1.4817 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="593" pm="."><plain>0.528 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="594" pm="."><plain>AT13387 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="595" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="596" pm="."><plain>6.2906 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="597" pm="."><plain>−9.1331 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="598" pm="."><plain>4.0913 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="599" pm="."><plain>0.415 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="600" pm="."><plain>Emodin </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="601" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="602" pm="."><plain>6.279 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="603" pm="."><plain>−0.6391 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="604" pm="."><plain>3.2784 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="605" pm="."><plain>0.440 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="606" pm="."><plain>2c </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="607" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="608" pm="."><plain>5.9724 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="609" pm="."><plain>−5.5461 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="610" pm="."><plain>0.0714 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="611" pm="."><plain>0.342 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="612" pm="."><plain>Pochonin D </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="613" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="614" pm="."><plain>5.8197 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="615" pm="."><plain>−3.0107 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="616" pm="."><plain>1.6854 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="617" pm="."><plain>0.406 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="618" pm="."><plain>o-RDC </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="619" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="620" pm="."><plain>5.743 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="621" pm="."><plain>−6.3103 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="622" pm="."><plain>1.714 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="623" pm="."><plain>0.393 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="624" pm="."><plain>Pochonin A </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="625" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="626" pm="."><plain>5.6544 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="627" pm="."><plain>−3.0449 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="628" pm="."><plain>1.7182 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="629" pm="."><plain>0.431 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="630" pm="."><plain>c-RDC </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="631" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="632" pm="."><plain>5.571 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="633" pm="."><plain>−3.8203 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="634" pm="."><plain>2.7142 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="635" pm="."><plain>0.353 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="636" pm="."><plain>Comp. </plain></SENT>
<SENT sid="637" pm="."><plain>18 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="638" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="639" pm="."><plain>5.2181 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="640" pm="."><plain>−0.9817 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="641" pm="."><plain>2.1991 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="642" pm="."><plain>0.381 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="643" pm="."><plain>KF25706 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="644" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="645" pm="."><plain>4.9578 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="646" pm="."><plain>−3.5256 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="647" pm="."><plain>2.2759 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="648" pm="."><plain>0.467 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="649" pm="."><plain>KF29163 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="650" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="651" pm="."><plain>4.8178 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="652" pm="."><plain>−2.5315 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="653" pm="."><plain>2.4504 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="654" pm="."><plain>0.406 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="655" pm="."><plain>RDC </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="656" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="657" pm="."><plain>4.2342 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="658" pm="."><plain>−2.6456 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="659" pm="."><plain>1.1539 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="660" pm="."><plain>0.421 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="661" pm="."><plain>Aigialomycin D </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="662" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="663" pm="."><plain>4.1481 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="664" pm="."><plain>−4.3331 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="665" pm="."><plain>4.1964 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="666" pm="."><plain>0.433 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="667" pm="."><plain>TSC24 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="668" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="669" pm="."><plain>4.1158 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="670" pm="."><plain>−0.8441 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="671" pm="."><plain>0.0514 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="672" pm="."><plain>0.392 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="673" pm="."><plain>Gambogic acid </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="674" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="675" pm="."><plain>3.8992 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="676" pm="."><plain>−7.3216 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="677" pm="."><plain>0.844 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="678" pm="."><plain>0.385 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="679" pm="."><plain>D11 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="680" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="681" pm="."><plain>−1.4678 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="682" pm="."><plain>−14.195 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="683" pm="."><plain>1.1678 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="684" pm="."><plain>0.361 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="685" pm="."><plain>KOSN1559 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="686" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="687" pm="."><plain>−2.5462 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="688" pm="."><plain>−14.8183 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="689" pm="."><plain>2.1768 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="690" pm="."><plain>0.428 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="691" pm="."><plain>GDM </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="692" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="693" pm="."><plain>−4.9652 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="694" pm="."><plain>−18.4653 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="695" pm="."><plain>2.1288 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="696" pm="."><plain>0.358 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="697" pm="."><plain>17-AAG </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="698" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="699" pm="."><plain>−6.3308 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="700" pm="."><plain>−17.5419 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="701" pm="."><plain>0.7688 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="702" pm="."><plain>0.478 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="703" pm="."><plain>17-DMAG </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="704" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="705" pm="."><plain>−8.4678 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="706" pm="."><plain>−21.6041 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="707" pm="."><plain>1.4689 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="708" pm="."><plain>0.508 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-bt-24-453"><label>1</label><p>Total Score represents the total Surflex-Dock score expressed as –log(<italic>K</italic><sub>d</sub>),</p></fn><fn id="tfn4-bt-24-453"><label>2</label><p>Crash is the degree of inappropriate penetration by the ligand into the protein between ligand atoms that are separated by rotatable bonds. Crash scores close to 0 are favorable,</p></fn><fn id="tfn5-bt-24-453"><label>3</label><p>Polar values show the contribution of the polar interactions to the total score,</p></fn><fn id="tfn6-bt-24-453"><label>4</label><p>Similarity indicates the difference between the top scoring pose and the original ligand (AMPPNP) used as the reference.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t5-bt-24-453" orientation="portrait" position="float"><label>Table 5.</label><caption><p><text><SENT sid="709" pm="."><plain>Hsp90 docking results of combined inhibitors </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="710" pm="."><plain>Name </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="711" pm="."><plain>Target </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="712" pm="."><plain>Total Score </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="713" pm="."><plain>Crash </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="714" pm="."><plain>Polar </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="715" pm="."><plain>Similarity </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="716" pm="."><plain>AUY922 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="717" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="718" pm="."><plain>11.3281 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="719" pm="."><plain>−2.9912 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="720" pm="."><plain>5.8905 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="721" pm="."><plain>0.566 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="722" pm="."><plain>KOSN1559 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="723" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="724" pm="."><plain>10.5386 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="725" pm="."><plain>−4.2057 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="726" pm="."><plain>6.0038 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="727" pm="."><plain>0.497 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="728" pm="."><plain>GDM </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="729" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="730" pm="."><plain>9.0405 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="731" pm="."><plain>−4.3587 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="732" pm="."><plain>5.7304 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="733" pm="."><plain>0.506 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="734" pm="."><plain>3t </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="735" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="736" pm="."><plain>8.9981 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="737" pm="."><plain>−1.9006 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="738" pm="."><plain>2.2646 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="739" pm="."><plain>0.451 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="740" pm="."><plain>KF58333 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="741" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="742" pm="."><plain>8.8035 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="743" pm="."><plain>−2.216 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="744" pm="."><plain>3.7782 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="745" pm="."><plain>0.475 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="746" pm="."><plain>PU3 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="747" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="748" pm="."><plain>8.6779 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="749" pm="."><plain>−1.3914 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="750" pm="."><plain>2.3162 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="751" pm="."><plain>0.465 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="752" pm="."><plain>Comp. </plain></SENT>
<SENT sid="753" pm="."><plain>14 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="754" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="755" pm="."><plain>8.0945 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="756" pm="."><plain>−2.9386 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="757" pm="."><plain>4.3295 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="758" pm="."><plain>0.547 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="759" pm="."><plain>o-RDC </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="760" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="761" pm="."><plain>7.4652 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="762" pm="."><plain>−3.5968 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="763" pm="."><plain>3.1916 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="764" pm="."><plain>0.421 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="765" pm="."><plain>CCT018159 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="766" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="767" pm="."><plain>7.4339 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="768" pm="."><plain>−0.7895 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="769" pm="."><plain>3.2601 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="770" pm="."><plain>0.521 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="771" pm="."><plain>SNX0723 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="772" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="773" pm="."><plain>7.1997 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="774" pm="."><plain>−2.4905 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="775" pm="."><plain>1.3399 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="776" pm="."><plain>0.526 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="777" pm="."><plain>Salvicine S </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="778" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="779" pm="."><plain>7.1362 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="780" pm="."><plain>−1.4093 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="781" pm="."><plain>1.6745 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="782" pm="."><plain>0.475 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="783" pm="."><plain>AT13387 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="784" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="785" pm="."><plain>7.1259 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="786" pm="."><plain>−2.0725 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="787" pm="."><plain>1.7217 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="788" pm="."><plain>0.519 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="789" pm="."><plain>Comp. </plain></SENT>
<SENT sid="790" pm="."><plain>14mod </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="791" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="792" pm="."><plain>7.0102 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="793" pm="."><plain>−2.3685 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="794" pm="."><plain>3.184 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="795" pm="."><plain>0.519 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="796" pm="."><plain>G3130 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="797" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="798" pm="."><plain>6.8551 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="799" pm="."><plain>−0.5655 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="800" pm="."><plain>4.089 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="801" pm="."><plain>0.514 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="802" pm="."><plain>QAP1 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="803" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="804" pm="."><plain>6.7837 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="805" pm="."><plain>−2.2874 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="806" pm="."><plain>0.9711 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="807" pm="."><plain>0.497 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="808" pm="."><plain>CPUY201112 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="809" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="810" pm="."><plain>6.7467 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="811" pm="."><plain>−2.5928 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="812" pm="."><plain>2.7711 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="813" pm="."><plain>0.612 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="814" pm="."><plain>NSC348400 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="815" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="816" pm="."><plain>6.7386 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="817" pm="."><plain>−1.4421 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="818" pm="."><plain>3.7083 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="819" pm="."><plain>0.511 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="820" pm="."><plain>RDC </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="821" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="822" pm="."><plain>6.6884 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="823" pm="."><plain>−2.5576 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="824" pm="."><plain>3.4177 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="825" pm="."><plain>0.666 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="826" pm="."><plain>NSC35866 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="827" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="828" pm="."><plain>6.649 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="829" pm="."><plain>−1.1619 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="830" pm="."><plain>2.6058 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="831" pm="."><plain>0.486 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="832" pm="."><plain>Salvicine R </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="833" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="834" pm="."><plain>6.4918 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="835" pm="."><plain>−2.4288 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="836" pm="."><plain>2.1968 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="837" pm="."><plain>0.510 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="838" pm="."><plain>Comp. </plain></SENT>
<SENT sid="839" pm="."><plain>1 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="840" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="841" pm="."><plain>6.4641 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="842" pm="."><plain>−1.627 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="843" pm="."><plain>2.2857 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="844" pm="."><plain>0.561 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="845" pm="."><plain>2c </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="846" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="847" pm="."><plain>6.4036 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="848" pm="."><plain>−3.4089 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="849" pm="."><plain>0.0014 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="850" pm="."><plain>0.329 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="851" pm="."><plain>KF25706 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="852" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="853" pm="."><plain>6.185 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="854" pm="."><plain>−2.8315 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="855" pm="."><plain>3.6404 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="856" pm="."><plain>0.647 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="857" pm="."><plain>Gambogic acid </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="858" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="859" pm="."><plain>6.0092 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="860" pm="."><plain>−2.2055 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="861" pm="."><plain>1.3905 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="862" pm="."><plain>0.297 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="863" pm="."><plain>Comp. </plain></SENT>
<SENT sid="864" pm="."><plain>2 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="865" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="866" pm="."><plain>5.952 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="867" pm="."><plain>−1.2823 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="868" pm="."><plain>1.4835 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="869" pm="."><plain>0.524 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="870" pm="."><plain>Daurinol </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="871" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="872" pm="."><plain>5.8292 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="873" pm="."><plain>−0.4604 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="874" pm="."><plain>1.3936 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="875" pm="."><plain>0.556 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="876" pm="."><plain>KF29163 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="877" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="878" pm="."><plain>5.7498 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="879" pm="."><plain>−2.3134 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="880" pm="."><plain>1.6213 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="881" pm="."><plain>0.530 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="882" pm="."><plain>17-DMAG </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="883" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="884" pm="."><plain>5.718 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="885" pm="."><plain>−3.6373 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="886" pm="."><plain>1.0756 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="887" pm="."><plain>0.318 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="888" pm="."><plain>c-RDC </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="889" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="890" pm="."><plain>5.6849 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="891" pm="."><plain>−3.5861 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="892" pm="."><plain>3.0525 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="893" pm="."><plain>0.691 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="894" pm="."><plain>Comp. </plain></SENT>
<SENT sid="895" pm="."><plain>5 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="896" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="897" pm="."><plain>5.6657 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="898" pm="."><plain>−1.6574 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="899" pm="."><plain>1.9241 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="900" pm="."><plain>0.430 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="901" pm="."><plain>D11 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="902" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="903" pm="."><plain>5.6512 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="904" pm="."><plain>−0.8901 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="905" pm="."><plain>2.5246 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="906" pm="."><plain>0.390 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="907" pm="."><plain>Emodin </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="908" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="909" pm="."><plain>5.6113 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="910" pm="."><plain>−0.429 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="911" pm="."><plain>1.9987 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="912" pm="."><plain>0.398 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="913" pm="."><plain>8-Cl-ATP </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="914" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="915" pm="."><plain>5.5933 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="916" pm="."><plain>−1.2132 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="917" pm="."><plain>4.7994 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="918" pm="."><plain>0.399 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="919" pm="."><plain>Pochonin D </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="920" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="921" pm="."><plain>5.5041 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="922" pm="."><plain>−1.5103 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="923" pm="."><plain>2.1344 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="924" pm="."><plain>0.550 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="925" pm="."><plain>TSC24 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="926" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="927" pm="."><plain>5.477 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="928" pm="."><plain>−1.2353 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="929" pm="."><plain>0.5795 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="930" pm="."><plain>0.418 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="931" pm="."><plain>Pochonin A </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="932" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="933" pm="."><plain>5.4494 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="934" pm="."><plain>−1.3695 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="935" pm="."><plain>2.6113 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="936" pm="."><plain>0.279 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="937" pm="."><plain>17-AAG </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="938" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="939" pm="."><plain>5.2911 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="940" pm="."><plain>−2.6657 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="941" pm="."><plain>0.545 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="942" pm="."><plain>0.301 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="943" pm="."><plain>Aigialomycin D </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="944" pm="."><plain>Hsp90 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="945" pm="."><plain>4.8757 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="946" pm="."><plain>−3.236 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="947" pm="."><plain>3.4461 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="948" pm="."><plain>0.549 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="949" pm="."><plain>Comp. </plain></SENT>
<SENT sid="950" pm="."><plain>18 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="951" pm="."><plain>Topo II </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="952" pm="."><plain>4.553 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="953" pm="."><plain>−0.4098 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="954" pm="."><plain>0.9114 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="955" pm="."><plain>0.427 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t6-bt-24-453" orientation="portrait" position="float"><label>Table 6.</label><caption><p><text><SENT sid="956" pm="."><plain>Docking analysis of selected inhibitors </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" valign="middle" align="center" rowspan="1"><text><SENT sid="957" pm="."><plain>Topo II </plain></SENT>
</text></th><th colspan="3" valign="middle" align="center" rowspan="1"><text><SENT sid="958" pm="."><plain>Hsp90 </plain></SENT>
</text></th></tr><tr><th colspan="3" valign="middle" align="center" rowspan="1"><text><SENT sid="959" pm="."><plain> </plain></SENT>
</text></th><th colspan="3" valign="middle" align="center" rowspan="1"><text><SENT sid="960" pm="."><plain> </plain></SENT>
</text></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="961" pm="."><plain>Name </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="962" pm="."><plain>Hydrophobic </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="963" pm="."><plain>Hydrogen bonding </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="964" pm="."><plain>Name </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="965" pm="."><plain>Hydrophobic </plain></SENT>
</text></th><th valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="966" pm="."><plain>Hydrogen bonding </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="967" pm="."><plain>PU3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="968" pm="."><plain>Asn91, Asp94, Arg98, Asn120, Ile125, Ile141, Phe142, Ser149, Asn150, Thr159, Gly161, Arg162, Gly164, Ala167, Lys168, Thr215 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="969" pm="."><plain>Asn91, Asn120, Ala167, Thr215 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="970" pm="."><plain>PU3 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="971" pm="."><plain>Asn51, Asp54, Ala55, Asp93, Ile96, Gly97, Met98, Asn106, Leu107, Gly135, Val136, Phe138, Val150, Thr184, Val186 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="972" pm="."><plain>Asp54, Thr184 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="973" pm="."><plain>3t </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="974" pm="."><plain>Asn91, Ala92, Asn95, Asn120, Pro126, Ile141, Phe142, Ser149, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215, Ile217 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="975" pm="."><plain>Asn91 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="976" pm="."><plain>3t </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="977" pm="."><plain>Asn51, Ala55, Lys58, Ile96, Gly97, Met98, Asn106, Phe138, Val150, His154, Thr184, Val186 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="978" pm="."><plain>Lys58, Gly97 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="979" pm="."><plain>Comp. </plain></SENT>
<SENT sid="980" pm="."><plain>14 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="981" pm="."><plain>Ile88, Asn91, Ala92, Asp94, Asn95, Ile118, Asn120, Ile125, Asn150, Gly161, Gly164, Tyr165, Ala167, Lys168, Thr215, Ile217 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="982" pm="."><plain>Asp94, Thr215 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="983" pm="."><plain>Comp. </plain></SENT>
<SENT sid="984" pm="."><plain>14 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="985" pm="."><plain>Asn51, Ser52, Ala55, Asp93, Ile96, Gly97, Met98, Asn106, Phe138, Val150, Thr184, Val186 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="986" pm="."><plain>Asp93, Gly97, Thr184 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="987" pm="."><plain>AUY922 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="988" pm="."><plain>Ile88, Asn91, Ala92, Asn95, Arg98, Ile118, Asn120, Ile125, Pro126, Ile141, Phe142, Ser149, Asn150, Gly161, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215, Ile217 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="989" pm="."><plain>Asn95, Asn120, Ser149 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="990" pm="."><plain>AUY922 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="991" pm="."><plain>Asn51, Ala55, Lys58, Asp93, Ile96, Gly97, Met98, Asp102, Leu107, Gly135, ValL136, Gly137, Phe138, Val150, Thr184, Val186 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="992" pm="."><plain>Asn51, Lys58, Asp93, Gly97, Phe138 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="993" pm="."><plain>8-Cl-ATP </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="994" pm="."><plain>Asn91, Asp94, Asn95, Arg98, Lys123, Gly124, Ile125, Ser149, Asn150, Gly161, Arg162, Asn163, Gly164, Tyr165, Gly166, Ala167, Gln376, Lys378 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="995" pm="."><plain>Asn91, Asp94, Asn150, Arg162, Tyr165, Gly166, Lys378 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="996" pm="."><plain>KOSN1599 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="997" pm="."><plain>Asn51, Ser52, Asp54, Ala55, Lys58, Asp93, Ile96, Met98, ASP102, Asn106, Leu107, Phe138, Thr184, Val186 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="998" pm="."><plain>Ser52, Asp54, Phe138 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t7-bt-24-453" orientation="portrait" position="float"><label>Table 7.</label><caption><p><text><SENT sid="999" pm="."><plain>Results of pharmacophore hypothesis generated by GASP </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="1000" pm="."><plain>Model </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="1001" pm="."><plain>Fitness </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="1002" pm="."><plain>Sizea </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="1003" pm="."><plain>Hitsb </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="1004" pm="."><plain>Dmeanc </plain></SENT>
</text></th><th valign="bottom" align="center" rowspan="1" colspan="1"><text><SENT sid="1005" pm="."><plain>Featuresd </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1006" pm="."><plain>1 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1007" pm="."><plain>2676.46 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1008" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1009" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1010" pm="."><plain>5.7693 </plain></SENT>
</text></td><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="1011" pm="."><plain>DS, AA, HY1, HY2 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1012" pm="."><plain>2 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1013" pm="."><plain>2689.23 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1014" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1015" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1016" pm="."><plain>3.5916 </plain></SENT>
</text></td><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="1017" pm="."><plain>DS, AA, HY1, HY2 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1018" pm="."><plain>3 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1019" pm="."><plain>2589.82 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1020" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1021" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1022" pm="."><plain>3.1774 </plain></SENT>
</text></td><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="1023" pm="."><plain>DS, AA, HY1, HY2 </plain></SENT>
</text></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1024" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1025" pm="."><plain>2663.25 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1026" pm="."><plain>2 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1027" pm="."><plain>4 </plain></SENT>
</text></td><td valign="middle" align="center" rowspan="1" colspan="1"><text><SENT sid="1028" pm="."><plain>4.5547 </plain></SENT>
</text></td><td valign="middle" align="left" rowspan="1" colspan="1"><text><SENT sid="1029" pm="."><plain>HY1, HY2 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tfn7-bt-24-453"><label>a</label><p>Number of features in the model,</p></fn><fn id="tfn8-bt-24-453"><label>b</label><p>Number of molecules that matched during the search,</p></fn><fn id="tfn9-bt-24-453"><label>c</label><p>Average interpoint distance,</p></fn><fn id="tfn10-bt-24-453"><label>d</label><p>Pharmacophore features. DS: donor site, AA: acceptor site, HY: hydrophobic.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
